Business News • PR NewsWire • Adding Novartis Drug Zometa® to Chemotherapy Significantly Improved Overall Survival in Study of Newly Diagnosed Multiple Myeloma Patients

Adding Novartis Drug Zometa® to Chemotherapy Significantly Improved Overall Survival in Study of Newly Diagnosed Multiple Myeloma Patients

Adding Novartis Drug Zometa® to Chemotherapy Significantly Improved Overall Survival in Study of Newly Diagnosed Multiple Myeloma Patients

EAST HANOVER, N.J., June 5 /PRNewswire/ -- New data to be presented tomorrow at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, show that the addition of Zometa® (zoledronic acid) to first-line chemotherapy significantly improved overall survival for

View More : http://www.prnewswire.com/news-releases/adding-novartis-drug-zometa-to-chemotherapy-significantly-improved-overall-survi...

Releted News by prnewswire

Solar Power 'Sets Sail' in Shanghai

New Analyses of Denosumab Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard of Care

Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting

Parents Magazine's Free Baby Photo Contest Ends June 19